Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ...

A new CRISPR breakthrough shows scientists can turn genes back on without cutting DNA, by removing chemical tags that act ...

Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...

The new Ryzen AI 400 series packs Zen 5 cores, RDNA 3.5 graphics, and XDNA 2 NPUs, promising faster AI performance and ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Massive endeavor including Hopkins researchers and students aims to understand the planet's most biodiverse habitats ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.